Dissecting the Decision: Investigators Discuss PARP Inhibition in the Management of Ovarian Cancer

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2017 Annual Meeting on Women’s Cancer. Featuring perspectives from Drs Robert L Coleman, Jonathan A Ledermann, Ursula A Matulonis and Richard T Penson.

1.75 AMA PRA Category 1 Credits^™

To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CME credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Related links:

Home
CME evaluation
CME information and faculty disclosures
Select publications
PowerPoint slides

Case discussion: A 72-year-old woman with BRCA2-mutated Stage IIIC mixed serous and endometrioid cancer experiences a non-ST-elevated myocardial infarction on the ARIEL2 trial of rucaparib
Presentation: Genomic Assessment in the Treatment of Ovarian Cancer — Dr Penson
Case discussion: A 61-year-old woman with high-grade recurrent platinum-sensitive serous ovarian cancer and a deleterious BRCA2 mutation responds to olaparib/cediranib with no evidence of disease
Presentation: PARP Inhibitor Monotherapy in Advanced Disease — Dr Matulonis
Closing: PARP Inhibitor Monotherapy in Advanced Disease — Dr Matulonis
Case discussion: A 64-year-old woman with Stage IIIB high-grade serous ovarian cancer and a somatic BRCA mutation receives niraparib on the NOVA trial
Presentation: Published and Emerging Research Data with PARP Inhibitor Maintenance Therapy — Dr Ledermann
Closing: Published and Emerging Research Data with PARP Inhibitor Maintenance Therapy — Dr Ledermann
Case discussion: A 75-year-old woman with Stage IV high-grade BRCA2 mutation-positive serous fallopian tube cancer has her olaparib dose and schedule adjusted due to fatigue and anemia
Presentation: Unique Tolerability Considerations Associated with PARP Inhibitors — Dr Coleman
Related symposium proceedings:
Dissecting the Decision: Investigators Discuss Current Management, Emerging Treatment Strategies and Novel Approaches in Gynecologic Cancers
1.25 Credits
Existing and Emerging Strategies in the Management of Patients with Uterine Sarcomas
2 Credits